{"prompt": "['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'TABLE OF TABLES', 'Table 1', 'Study Objectives and Endpoints', '20', 'Table 2', 'Study Treatments', '29', 'Table 3', \"Investigator's Global Assessment Score (5-Point Scale)\", '39', 'Table 4', 'Dermatology Life Quality Index Scale', '40', 'Table 5', \"Children's Dermatology Life Quality Index Scale\", '41', 'Table 6', 'Analysis Sets', '47', 'Table 7', 'Protocol-Required Safety Laboratory Assessments', '62', 'Table 8', 'Highly Effective Contraceptive Methods', '70', '6']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', '1.0', 'PROTOCOL SUMMARY', '1.1', 'Synopsis', 'Protocol Title: A Randomized, Parallel, Double-Blind Vehicle-Controlled Study to Evaluate the Safety', 'and Efficacy of Two Concentrations of Topical TMB-001 for the Treatment of Congenital Ichthyosis', 'Short Title: A Vehicle-Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for', 'Treatment of Congenital Ichthyosis', 'Rationale:', 'Timber Pharmaceuticals, LLC, is developing a topical ointment (0.05% and 0.1%) formulation of', 'isotretinoin called TMB-001 (previously PAT-001) (isotretinoin) ointment for the treatment of congenital', 'ichthyosis (CI), including recessive X-linked ichthyosis (RXLI) and autosomal recessive congenital', 'ichthyosis-lamellar ichthyosis (ARCI-LI) subtypes. The purpose of this study is to investigate the efficacy', 'and safety of two concentrations of topically applied TMB-001 in subjects 9 years of age and older.', 'Objectives and Enppoints', 'Objectives', 'Enppoints', 'Efficacy', 'Primary Efficacy', 'To investigate the efficacy of two concentrations', 'Proportion of subjects with Visual Index for', 'of topically applied TMB-001 as a treatment for', 'Ichthyosis Severity - \"treatment success\" (VIIS-', 'congenital ichthyosis (CI) of either the autosomal', '50), which is defined as a 50% or greater decrease', 'recessive congenital ichthyosis-lamellar ichthyosis', 'in VIIS scaling score relative to Baseline at Visit 6', '(ARCI-LI) or RXLI subtypes.', '(EOS) calculated using the sum of the scores for', '\"VIIS body areas\\' that have a Baseline score > 3.', 'Key Secondary Efficacy', 'IGA scores, dichotomized to \"treatment success\"', 'or \"treatment failure\" where \"treatment success\" is', 'defined as at least a 2-grade decrease in severity', 'score relative to Baseline at Visit 6 (EOS).', 'Other Secondary Efficacy', 'Time to achieve VIIS-50 (> 50% reduction in VIIS', 'scaling score for body sites that had a Baseline', 'score > 3) that is maintained at the next', 'observation.', 'Changes in VIIS scaling score relative to Baseline', 'at Visit 4 and Visit 5.', 'Proportion of subjects with IGA \"treatment', 'success\" at Visit 4, Visit 5, and Visit 6 (EOS).', 'Proportion of subjects with an IGA score of 0 or 1', 'representing \"cleared\" or \"almost cleared\" at', 'Visit 6 (EOS).', 'Changes in percent BSA relative to Baseline with', 'CI in the Treatment/Assessment Areas at Visit 3,', 'Visit 4, Visit 5, and Visit 6 (EOS).', 'Change from Baseline in Itch-Numeric Rating', 'Scale (I-NRS) score at Visit 6 (EOS).', 'Proportion of subjects with I-NRS \"treatment', 'success\" where \"success\" is defined as at least a', '7']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'Objectives', 'Enppoints', '4-point reduction in I-NRS relative to Baseline at', 'Visit 6 (EOS).', 'Change in DLQI from Baseline to Visit 6 (EOS).', 'Safety', 'Safety', 'To investigate the safety of topically applied', 'Incidence (severity and causality) of any local and', 'TMB-001.', 'systemic AEs.', 'Number of subjects with presence (and severity) at', 'each time point of the LSRs including', 'burning/stinging, erythema, erosions, and edema.', 'Changes from Baseline in vital signs at Visit 6', '(EOS).', 'Changes from Baseline in clinical laboratory test', 'results (chemistry, hematology, and urinalysis) at', 'Visit 6 (EOS).', 'Abbreviations: AE = adverse event; ARCI-LI = autosomal recessive congenital ichthyosis-lamellar ichthyosis;', 'BSA = body surface area; CI = congenital ichthyosis; DLQI = Dermatology Life Quality Index; EOS = End of', \"Study; IGA = Investigator's Global Assessment; I-NRS = Itch-Numeric Rating Scale; LSR = local skin\", 'reaction; RXLI = recessive X-linked ichthyosis; VIIS = Visual Index for Ichthyosis Severity.', 'Overall Design:', 'This is a randomized, parallel, double-blind, vehicle-controlled study to evaluate the safety and efficacy of', 'two concentrations of topical TMB-001 for the treatment of CI in subjects with either the ARCI-LI or RXLI', 'subtypes. The duration of treatment will be 12 weeks. Each subject will participate in the study for up to', '24 weeks (including up to a 90-day Screening period).', 'Number of Investigators and Study Centers:', 'Approximately 10 study centers from United States of America and Australia are expected to participate', 'in this global study.', 'Number of Subjects:', 'Approximately 45 subjects will be enrolled (15 per treatment arm).', 'Treatment Groups and Duration:', 'Each subject will participate in the study for up to 24 weeks (including up to a 90-day Screening period).', 'Eligible subjects will be randomized (1:1:1) to one of 3 treatment groups:', '1.', 'TMB-001, 0.05%, twice daily (bid)', '2. TMB-001, 0.1%, bid', '3. Vehicle Ointment (Control), 0%, bid', 'Temporary Discontinuation (Drug Interruption/Holiday)', 'A treatment interruption scheme will be allowed if a subject experiences skin adverse events or local skin', 'reactions (LSRs) during the study that may require interruption or termination of study medication. This is', 'intended to assist subjects to continue in the study if the event is likely or expected to lead to discontinuation.', 'Any subjects with a local AE (especially early during treatment) will be encouraged to continue with their', 'study medication since transient skin irritation is known to develop with topical retinoids, but AEs may also', 'develop due to the vehicle formulation or otherwise.', 'It is desirable to make every effort to maintain subjects in the study to allow adequate assessment of efficacy', 'and safety, especially in this small dose ranging study. If during the Treatment Phase there is for example', 'a persistent Grade 2 or greater burning/stinging, erythema, erosions, edema or pruritus, treatment will be', '8']\n\n###\n\n", "completion": "END"}